NY-VECTORMAX
16.6.2020 15:19:11 CEST | Business Wire | Press release
IENTC Telecomunicaciones , an internet and television service provider operating in the Mexican market, today announced it is launching VectorMax’s turn-key IPTV Platform as the software to support its new television product. Serving the market for more than 10 years, IENTC Telecomunicaciones’ new service augmenting its consumer offering reflects the growing shift from broadcast television to IP delivery of live linear TV.
This marks the first commercial deployment of an all software solution enabling operators to transition from broadcast to online delivery of live linear television without having to upgrade their network architecture. The software leverages $73M of R&D from teams out of MIT, IBM Labs, Bell Labs, DARPA and MPEG related projects to deliver multicast live linear as a turn-key, fully integrated, multicast software platform for cable operators, telcos, and high-speed access providers.
“Operators need to transition and support their entertainment experiences to remain relevant and competitive,” said Peter von Schlossberg, VectorMax’s President Global Product. “Our operators are searching for solutions to deliver a live linear consumer experience side-by-side with SVOD offerings from Netflix, Hulu, Amazon, Google, etc. VectorMax developed a unique software solution that capitalizes on existing infrastructure and networks to deliver high-quality live linear broadcast & other IP services.
“Transitioning to online delivery of live linear can be daunting, but VectorMax’s software platform allowed us to quickly see our consumer offering ingested and delivered in multicast by the VectorMax software. Our own branded Streaming Media Player apps on Amazon FireTV, Roku, Android STBs, Smart TVs and iOS were live within weeks. VectorMax’s ‘show-me’ sales strategy enabled us to easily determine they were the best fit to support the growing demands of our customers,” said Carlos Arguimbau, CEO of IENTC.
VectorMax’s ability to execute technological and marketing solutions with minimal disruption to our existing operations assured us that they were an important resource to navigate new market dynamics. The end product is a win-win for both IENTC and our customers,” said Arguimbau.
IENTC’s new +TV service is bolstered by a recent study from Hub Entertainment Research. The study found that the average number of television services accessed online per viewer in the US in the past 24 months reflected a rise of over 50%. That number is expected to trend globally. IENTC is also tracking the Hub findings reflecting pay-TV subscribers who have used an operator provided set-top box to watch streaming services tend to keep using it; 58% do so to access Netflix, 61% for Amazon, and 57% for Hulu.
“These findings are a key validation of providers’ efforts to aggregate streaming services as another way to create value in the set-top box and reduce cord-cutting”, said von Schlossberg.“VectorMax deployed our Platform in December which is now being expanded to a wider area of IENTC’s footprint in Mexico. Strategically, we are positioned to help cable companies and telecoms address this shift and to market new services as easily as flicking on a switch. The VectorMax Platform is slated for a roll-out to additional customers starting Q3 2020”.
About VectorMax Corporation
VectorMax’s pioneering of technologies that increase the efficiencies in delivering IP video over large scale, fully developed, and imperfect networks, solves the evolution of live linear broadcast television to on-network online delivery. The Company holds 102 worldwide patents grounded in software-based IP transport delivery technologies.
Supported with $73 million of R&D and twelve years of intensive research and development, conducted by a development team with MIT, IBM Labs, Bell Labs, DARPA & MPEG credentials, the Company delivers a complete end to end platform comprised of multiple modules designed to work together to deliver IPTV to large scale audiences over less than optimal networks within bandwidth constrained and limited infrastructure environments. The carrier requires no other third-party component to ingest, encode, manage and deliver the immersive experience that 2020 subscribers expect. Discover more at www.vectormax.com .
About IENTC Telecomunicaciones
IENTC Telecomunicaciones is a company with more than 10 years in the telecommunications industry located in the central zone of Mexico. With high-speed internet that is offered through its’ own fiber-optic network, providing best in class service and a customer experience that guarantees business is always connected. IENTC has the most advanced technology available in the market, which enables the offering of additional services such as Mobile phone, Virtual PBX, Smart Internet, and Television services among others. Discover more at ientc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005227/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom